Advances in molecular psychiatry are sharpening scientists’ view of how stress and drugs can leave long-lasting marks on the brain. A recent interview published by Genomic Press in the journal Brain Medicine highlights decades of work that helped connect fleeting experiences to persistent changes in behavior.
In the discussion, neuroscientist Eric J. Nestler, dean of the Icahn School of Medicine at Mount Sinai, traces how early training in brain chemistry led him to focus on the biology behind addiction, depression and resilience. He describes a field that has moved from broad theories toward specific molecules, cell types and circuits that can be measured.
ΔFosB and long-term brain change
One of the best-known findings from this line of research centers on ΔFosB, a transcription factor that can build up in reward-related brain circuits after repeated drug exposure and prolonged stress. Unlike many proteins that degrade quickly, ΔFosB can persist for weeks, helping to explain how short periods of exposure may trigger longer-lasting shifts in gene activity.
Researchers have linked this durability to changes in motivation and reward processing that can raise vulnerability to addiction. The idea is not that one factor explains complex disorders, but that stable molecular signals like ΔFosB can act as a biological bridge between experience and enduring neural adaptation.
From epigenetics to single-cell tools
Nestler also points to a major methodological shift in the field, from studying signaling pathways to mapping gene regulation through epigenetic mechanisms such as chromatin modifications. Those approaches have been accelerated by tools that can parse differences across brain regions and, increasingly, across individual neuron types.
Single-cell methods are now enabling researchers to look for patterns that may be missed when tissue is analyzed in bulk. That trajectory is feeding interest in whether future treatments could be tailored more precisely to particular circuits or cell populations involved in mood and substance-use disorders.
Why resilience is becoming central
A notable theme in the interview is a push to study resilience, not only pathology. Experiments in animals have identified molecular and circuit signatures associated with maintaining normal behavior despite stress, raising the possibility of therapies designed to strengthen protective mechanisms.
Some resilience-oriented strategies are already being tested clinically for depression, reflecting a broader shift toward interventions that aim to improve adaptive capacity as well as relieve symptoms. The interview argues that focusing on what helps certain individuals recover could open complementary pathways for drug development.
Nestler also underscores the importance of linking animal findings with human evidence, including results from postmortem brain studies in people affected by addiction and stress-related conditions. He warns that politicizing science could slow progress, stressing that medical research should remain independent and broadly beneficial.
